Allergan, Richter Get FDA Approval for Expanded Use of Vraylar

Allergan and Gedeon Richter received FDA approval for expanded use of Vraylar (cariprazine) in the treatment of bipolar depression.

• Vraylar is also approved in the U.S. to treat manic or mixed episodes associated with bipolar I disorder in adults
• Richter shares reverse declines after FDA ruling on Vraylar
• Link to Statement: Allergan and Gedeon Richter Receive U.S. FDA Approval For Expanded Use of VRAYLAR® (cariprazine) in the Treatment of Bipolar D

©2019 Bloomberg L.P. All rights reserved. Used with permission